ArticleJournal of neurochemistry2025
Multiple Mammalian Cytokines and Erythropoietin-Mimetic Peptides Protect Insect Neurons via Phylogenetically Conserved Cytokine Receptor-Like Factor 3 (CRLF3).
Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Osteoarthritis and dementia: contrasting disorders driven by mutual pathways of autophagy, mTOR, GLP-1, AMPK, Wnt, and WISP1.Expert review of clinical pharmacology · 2026Review
- Running out the clock: Circadian rhythm dysfunction in cognitive disease.International review of neurobiology · 2026Review
- Multiple Mammalian Cytokines and Erythropoietin-Mimetic Peptides Protect Insect Neurons via Phylogenetically Conserved Cytokine Receptor-Like Factor 3 (CRLF3).Journal of neurochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Erythropoietin (Epo) and its non-erythropoietic splice variant EV-3 have demonstrated potent neuroprotective effects across species, although the respective mechanisms are variable and incompletely understood. Unlike vertebrates, insects lack both Epo and the classical Epo receptor but express Cytokine Receptor-Like Factor 3 (CRLF3), a conserved type I receptor that serves as a neuroprotective receptor for Epo and EV-3 in insects and human iPSC-derived neuron-like cells. Insects, which express CRLF3 but lack all other group 1 type I cytokine receptors, represent a suitable model to study the function of CRLF3 in neuroprotection. Previous experiments with primary brain neurons from the locust Locusta migratoria demonstrated that human Epo and EV-3 prevented hypoxia-induced apoptosis via activation of CRLF3 and downstream signaling mediated by JAK/STAT activity. Here we demonstrate that locust neurons are also protected by three small peptides (≤ 20 amino acids) with previously established erythropoietic and/or neuroprotective capacities in mammals. These peptides included non-erythropoietic HBSP and P16, as well as erythropoietic EMP1. To further characterize the ligand spectrum of locust CRLF3, we tested specific ligands of vertebrate group 1 type I cytokine receptors for their neuroprotective potential. While human thrombopoietin protected locust neurons via activation of CRLF3, human prolactin and growth hormone showed no anti-apoptotic effects. Our findings highlight CRLF3 as a versatile neuroprotective receptor that can be activated by the three natural human cytokines Epo, EV-3, and thrombopoietin, and three artificial short peptides with and without erythropoietic activity. In contrast to vertebrate classical Epo receptor, which is only activated by Epo and EMP1, CRLF3 has an extended and more generalist ligand spectrum to mediate neuroprotection. This wide ligand spectrum may support the hypothesis of CRLF3 being the evolutionary precursor of various vertebrate-specific cytokine receptors and may qualify this more general cell protective receptor as a target for pharmacological intervention in neurodegenerative processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.